Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study

Jatinder K Lamba, PhD, Lata Chauhan, PhD, Michael R. Loken, PhD, Jessica Pollard, MD, Yi-Cheng Wang, MS, Ries E Rhonda, Richard Aplenc, MD PhD, Betsy A. Hirsch, PhD, Susana C. Raimondi, PhD, Roland B. Walter, MD PhD, Irwin D. Bernstein, MD, Alan S. Gamis, MD MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD PhD

Blood (2016) 128 (22): 2743.

https://doi.org/10.1182/blood.V128.22.2743.2743

Published: 2016

Journal Articles

Relapse Following Initial Remission and Subsequent Outcome for Children with Relapsed Acute Myeloid Leukemia on the AAML0531 Phase III Study of Gemtuzumab Ozogamicin: A Report from the Children's Oncology Group

Todd M Cooper, DO, Robert B. Gerbing, MA, Todd A. Alonzo, PhD, Jessica Pollard, MD, Lillian Sung, MD PhD FRCPC, E. Anders Kolb, MD, Richard Aplenc, MD PhD, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH

Blood (2016) 128 (22): 2794.

https://doi.org/10.1182/blood.V128.22.2794.2794

Published: 2016

Journal Articles

Mutational Concordance from Diagnosis and Relapse in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Katherine Tarlock, MD, Todd M Cooper, DO, Todd A. Alonzo, PhD, Robert Gerbing, BS, Jessica Pollard, MD, Richard Aplenc, MD PhD, E. Anders Kolb, MD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD

Blood (2016) 128 (22): 2846.

https://doi.org/10.1182/blood.V128.22.2846.2846

Published: 2016

Journal Articles

Prognostic Significance of 11q23/ MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531

Erin M. Guest, MD, Betsy A. Hirsch, PhD, E. Anders Kolb, MD, Todd A. Alonzo, PhD, Robert Gerbing, BS, Richard Aplenc, MD PhD, Jessica Pollard, MD, Lillian Sung, MD PhD FRCPC, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH, Susana C. Raimondi, PhD

Blood (2016) 128 (22): 1211.

https://doi.org/10.1182/blood.V128.22.1211.1211

Published: 2016

Journal Articles

The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group

Richard Aplenc, MD PhD, Soheil Meshinchi, MD PhD, Lillian Sung, MD PhD FRCPC, Todd A. Alonzo, PhD, Jessica Pollard, MD, Robert Gerbing, BS, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Michael R. Loken, PhD, Laura Winter, PharmD, Samir B. Kahwash, John K Choi, MD, John E Levine, MD MS, E. Anders Kolb, MD, Alan S. Gamis, MD MPH

Blood (2016) 128 (22): 899.

https://doi.org/10.1182/blood.V128.22.899.899

Published: 2016

Journal Articles

Genetic Variations in Calicheamicin Pathway Genes Are Predictors of Gemtuzumab Ozogamicin Response in AML Patients: Results from COG-AAML0531 Study

Jatinder K Lamba, PhD, Lata Chauhan, PhD, Richard Aplenc, MD PhD, Maggie Skrypek, MD, Jessica Pollard, MD, Todd A. Alonzo, PhD, Y-C Wang, Irwin D. Bernstein, MD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD

Blood (2015) 126 (23): 1260.

https://doi.org/10.1182/blood.V126.23.1260.1260

Published: 2015

Journal Articles

Treatment of 11q23/ MLL + AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531

Jessica Pollard, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Lillian Sung, MD PhD, Richard Aplenc, MD PhD, Erin M. Guest, MD, Irwin D. Bernstein, MD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH

Blood (2015) 126 (23): 799.

https://doi.org/10.1182/blood.V126.23.799.799

Published: 2015

Journal Articles

Prevalence and Prognostic Significance of KIT Mutations in Pediatric Core Binding Factor AML Patients Treated with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531

Jessica Pollard, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Yi-Cheng Wang, MS, Jason Joaquin, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Lillian Sung, MD PhD, Richard Aplenc, MD PhD, Irwin D. Bernstein, MD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD

Blood (2015) 126 (23): 800.

https://doi.org/10.1182/blood.V126.23.800.800

Published: 2015

Journal Articles

Sorafenib Treatment Following Hematopoietic Stem Cell Transplant In Pediatric FLT3/ITD+ AML

Jessica Pollard, MD, Bill H Chang, MD, PhD, Todd Michael Cooper, Thomas Gross, MD, PhD, Sumit Gupta, MD, Phoenix A. Ho, MD, Suzanne M. McGoldrick, MD, Tanya C. Watt, MD, MSc, India Sisler, MD, Blythe Thomson, MD, Ann E Woolfrey, MD, Soheil Meshinchi, MD, PhD

Blood (2013) 122 (21): 3969.

https://doi.org/10.1182/blood.V122.21.3969.3969

Published: 2013

Journal Articles

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Todd Michael Cooper, Sharyn D. Baker, PharmD, PhD, Jennifer Direnzo, Tanya M. Trippett, Lia Gore, MD, Aru Narendran, MD, PhD, Keith J. August, M.D., M.Sc., Michael J. Absalon, MD, PhD, Jessica Boklan, MD, Jessica Pollard, MD, Daniel Magoon, Edward Allan R. Sison, MD, Patrick Brown, MD

Blood (2013) 122 (21): 2680.

https://doi.org/10.1182/blood.V122.21.2680.2680

Published: 2013

Journal Articles

Negative Prognostic Impact Of High CD33 Expression Is Negated With The Use Of Gemtuzumab Ozogamicin: A Report From The Children’s Oncology Group

Jessica Pollard, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Susana C Raimondi, PhD, Betsy Hirsch, PhD, Richard Aplenc, MD, Alan S. Gamis, MD, MPH, Michael R. Loken, PhD, Soheil Meshinchi, MD, PhD

Blood (2013) 122 (21): 491.

https://doi.org/10.1182/blood.V122.21.491.491

Published: 2013

NARROW

CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study

Relapse Following Initial Remission and Subsequent Outcome for Children with Relapsed Acute Myeloid Leukemia on the AAML0531 Phase III Study of Gemtuzumab Ozogamicin: A Report from the Children's Oncology Group

Mutational Concordance from Diagnosis and Relapse in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Prognostic Significance of 11q23/ MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531

The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group

Genetic Variations in Calicheamicin Pathway Genes Are Predictors of Gemtuzumab Ozogamicin Response in AML Patients: Results from COG-AAML0531 Study

Treatment of 11q23/ MLL + AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531

Prevalence and Prognostic Significance of KIT Mutations in Pediatric Core Binding Factor AML Patients Treated with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531

Sorafenib Treatment Following Hematopoietic Stem Cell Transplant In Pediatric FLT3/ITD+ AML

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Negative Prognostic Impact Of High CD33 Expression Is Negated With The Use Of Gemtuzumab Ozogamicin: A Report From The Children’s Oncology Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only